Dr. Axel Hoos, SVP
Axel Hoos, MD, PhD

SVP, Oncology R&D

A career in Oncology

GSK Oncology has a commitment to the discovery and development of new oncology therapies with the life-changing potential of helping patients with cancer, specifically in three areas of cancer research: Cancer Epigenetics, Immuno-Oncology, and Oncology Cell Therapy. We have a need to recruit professionals to fill a variety of roles.

GSK Oncology is committed to discovering and developing new medicines for patients with cancer.
Join us."

R&D scientists

Opportunities

Join us in Oncology to help improve the lives of patients around the world. We have vacancies in the U.S., U.K. and mainland Europe. Search our global career finder to see all vacancies in this area.

Job search finder

Join us

If you are an expert in one of the fields below, we have a role for you. Our vacancies regularly include opportunities for:

Commercial Insights & Analytics Medical Information
Communications Medical Science Liaisons
Finance Physicians (Drug Development & Medical Affairs)
Health Economics & Outcomes Research Scientific Directors (Drug Development & Medical Affairs)
Marketing & Sales Regulatory Affairs

Why GSK?

As a science-led, global healthcare business with clear values, we offer countless opportunities for people at various stages of their careers. On-the-job learning and rewarding individual contributions are extremely important to us. We believe in creating an inclusive and safe working environment and supporting our employees to help their communities.

We focus on creating an inclusive organization where all employees feel engaged and know their work makes an important contribution. An inclusive environment welcomes different knowledge, perspectives, experiences and working styles from across our global population. This not only enhances individual creativity and innovation but makes good business sense.

The future of oncology at GSK

Hear from Axel Hoos, Sr. VP of R&D in Oncology at GSK as he describes how GSK plans to help patients with cancer to not only live but live well. 

See what we’re doing in Oncology

Hal Barron

GSK announces a global strategic alliance

Find out how our global strategic alliance with Merck KGaA, Darmstadt, Germany to jointly develop and commercialize a potential first-in-class immunotherapy could potentially bring new answers to patients living with cancer.

Read our press release to learn more.

Hal Barron

GSK completes acquisition of TESARO

We’re very excited to announce that we have successfully completed the acquisition of TESARO Inc, an oncology-focused company. We look forward to accelerating the delivery of transformational medicines to patients with cancer, together.

Read our press release to learn more.

Emma Walmsley

GSK to acquire TESARO

GSK recently announced an agreement to acquire TESARO, an oncology focused company based in the US. The proposed transaction will strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology.

Learn more about GSK's agreement to acquire TESARO on our global site

Dr Hal Barron, GSK
Hal Barron, Chief Scientific Officer and President, R&D

A new approach to R&D at GSK

Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update at Q2 results in July 2018.

View presentation - A new approach to research and development at GSK

Go behind the scenes

See what it means to our scientists to be at the forefront of the drug development process.